Cleveland, Ohio 2021-09-17 05:27:10 –
In a document posted online, the FDA noted inconsistent data about boosters.
“Some observational studies suggest reduced efficacy of COMIRNATY for symptomatic treatments or delta mutants, but others do not,” the FDA said in a briefing document.
Comirnaty, which refers to Pfizer’s COVID-19 vaccine, Combination of terms COVID-19, mRNA, community and immunity.
Data submitted Pfizer Break’s report to the FDA shows the effects experienced after the booster. Pfizer asked study participants to submit their symptoms using an electronic diary.
According to the company, pain at the injection site was the most common side effect.
Pfizer said most side effects lasted up to two days.
It is said that severe side effects are rarely reported, but when reported, it was severe fatigue and myalgia. Study participants aged 18-55 were most likely to report side effects.
|Symptoms||18-55 years old||65-85 years old|
|Injection site pain||83%||66.7%|
Other side effects that were not felt less often were chills and new / worsened joint pain.
Several studies supporting boosters have been conducted in Israel, and the FDA also states that US-based studies “may best represent the effectiveness of vaccines in the US population.” Note that.
NS FDA said The data they have available have shown that the vaccine remains effective in preventing serious illness.
Suggest a fix
Pfizer COVID-19 booster side effects Source link Pfizer COVID-19 booster side effects